Plain-English translation of NCT07705074 on ClinicalTrials.gov ↗ · Source last updated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
Switzerland
Phase
Safety & dosing / Early efficacy
Sponsor
Martin Huellner
Collaborators
University Hospital, Zürich
Enrollment target
~770 participants
Started
August 2026
Primary completion
September 2029
Age range
18 Years and older
Last updated on clinicaltrials.gov in July 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Martin Hüllner, Prof. Dr. med.
Department for Nuclear Medicine, University Hospital Zurich
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.